楊志新 教授

 
專長:
  1. 基礎腫瘤醫學
  2. 臨床腫瘤醫學
  3. 抗癌藥物發展
  4. 化學藥物抗藥性
  5. 臨床試驗
 
現職:
  • 台大醫學院臨床醫學研究所教授
  • 台大醫學院臨床藥學研究所教授
  • 台大醫學院腫瘤醫學研究所教授
  • 台大醫學院附設醫院腫瘤醫學部副主任
  • 台大醫學院癌症研究中心主任
 
學歷:
  • 國立台灣大學醫學系醫學士
  • 國立台灣大學臨床醫學研究所博士
 
電話: 886-2-23123456 #67511
傳真: 886-2-23711174
電子信箱: chihyang@ntu.edu.tw
個人網址: http://oncology.ntu.edu.tw/people/bio.php?PID=6
 
簡介:
    楊志新教授目前擔任台大醫學院癌症防治中心主任,是腫瘤醫學研究所、臨床醫學研究所、臨床藥學研究所合聘教授,也擔任台大醫院腫瘤醫學部副主任。楊醫師的研究主要是肺癌臨床的研究及基礎醫學中癌症抗藥性的機轉。在臨床研究方面,楊醫師在國內執行許多肺癌的臨床試驗,已刊登在國際知名的雜誌如New England Journal of Medicine、Journal of Clinical Oncology、Journal of Thoracic Oncology等。楊醫師在數年間,得到國科會、國衛院許多計劃,並和諸多跨國藥廠合作,進行國際多中心臨床試驗,提昇台灣在國際癌症研究學界之知名度。經由這幾年的努力,他已在世界肺癌治療上有極高的知名度,參與設計並主導許多大型的跨國臨床試驗,並擔任試驗中重要委員會的成員。近年來由於肺癌台灣研究團隊優秀的表現,楊醫師已受邀至歐美參與設計大型的跨國臨床試驗,至大型會議作演講,及至美國癌症中心作學術演講交流,受邀國際演講已超過八十次。楊志新教授領導的台灣肺癌臨床試驗團隊,在第二代不可逆EGFR-TKI在肺癌的臨床研究,領先世界各國。他也因此常受邀審查New England Journal of Medicine、Journal of Clinical Oncology、Cancer Research 等相關投稿論文;同時擔任世界肺癌研究學會會刊Journal of Thoracic Oncology的編輯。近年來,楊教授的團隊致力於肺癌早期臨床試驗的推動及轉譯醫學的研究,已有數件早期試驗進行中。因楊教授常受邀參加國際新藥開發的專家會議,對於新藥之引進有相當的經驗。
 
代表性著作:
  1. Lin CC and Yang CH*. Optimal management of patients with nonsmall cell lung cancer and EGFR mutation. Drug 2011;71(1)79-88  (*Corresponding author)
  2. de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, DeMarinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J and Vansteenkiste J Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL) J Clin Oncology 2011 10:39(8):1067-74
  3. Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, Yu YL, Lan CC, Yang CH, Lin SB, Wu CP, Shih JY, Yang PC. Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Am J Respir Crit Care Med. 2011;183(8):1071-9
  4. Wu JY, Wu SG, Yang CH, Chang YL, Chang YC, Hsu YC, Shih JY, Yang PC. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutation. Lung Cancer 2011;72(2):205-12
  5. Lee LJ, Chung CW, Chang YY, Lee YC, Yang CH, Liou Sh, Liu PH, Wang JD. Comparison of the quality of life between patients with non-small cell lung cancer and healthy controls. Qual Life Res 2011;20(3):415-23
  6. Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH, Yu CJ and Yang PC. Thymidylate synthase and dihydrofolate reductase expression in nonsmall cell lung cancer carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011 (e-publish)
  7. Lin ZZ and Yang CH*. Current Roles and Future Perspectives of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer. Eur J Clin Med Oncol 2011 March online publish (*Corresponding author)
  8. Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer. Results of an Exploratory Subgroup Analysis of a Phase III Trial. Journal of Thoracic Oncology 2010;5(5):688-695
  9. Wu SG, Yang CH, Yu CJ, Lee JH, Hsu YC, Chang YL, Shih JY and Yang PC. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 2010 (accepted)
  10. Sequist LV and Yang CH. A randomized phase III trial of BIBW 2992 versus chemotherapy as first-line treatment for stage IIIB/IV adenocarcinoma of the lung harboring and epidermal growth factor receptor-activating mutation. Community Oncology 2010;7:1-4
  11. Lin CC, Hsu HH, Sun CT, Shih JY, Lin ZZ, Yu CJ, Chen GG, Hsin MK, Lam KC, Leung L, Yang CH* and Mok T. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild type or activating mutation of epidermal growth factor receptors Journal of Thoracic Oncology 2010;5(9):1424-9 (*corresponding author)
  12. Wu JY, Yang CH, Hsu YC, Yu CJ, Chang SH, Shih JY, Yang PC. Use of cetuximab after failure of gefitinib in patients with advanced non-small cell lung cancer. Clin Lung Cancer. 2010 Jul 1;11(4):257-63.
  13. Shao YY, Lin CC, Yang CH*. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. Discov Med 2010;9(49):538-45 (*corresponding author)
  14. Shao YY, Hu FC, Liang JT, Chiu WT, Cheng AL, Yang CH*. Characteristics and risk factors of oxaliplatin-related hypersensitivity reaction. J Formos Med Assoc 2010;109(5):362-8 (*corresponding author)
  15. Lee JH, Yu CJ, Chen KY, Shih JY, Lin YL, Yang CH*. Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer. J Formos Med Assoc 2010;109(5):338-44 (*corresponding author)
  16. Chen KY, Chen JH, Shih JY, Yang CH, Yu CJ, Yang PC.. octagenarians with advanced non-small cell lung cancer treatment modalities, survival and prognostic factors. Journal of Thoracic Oncology 2010;5(1):82-9
  17. Cho BC, Kim JH, Soo RA and Yang CH*. The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer Yonsei Med J 51(1):1-8,2010 (review) (*corresponding author)
  18. Wu JY, Shih JY, Yang CH, Chen KY, Ho CC, Yu CJ, Yang PC. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer 2010;126(1):247-55
  19. Wu JY, Yu CJ, ShihJY, Yang CH and Yang PC. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer 2010;67(3):348-54
  20. Huang CT, Yen RF, Cheng ME, Hsu YC, Wei PF, Tsai YJ, Tsai MF, Shih JY, Yang CH, Yang PC. Correlation of F-18-flurodeoxyglucose-positron emission tomography maximal standardization uptake value and EGFR mutations in advanced lung adenocarcinoma. Medical Oncology, 2010;27(1):9-15
  21. Gainford MC, Yang CH, Liu MY et al. Translation and cultural adaptation of the patient disease and treatment assessment form. A novel quality of life instrument for use in Taiwan Asia Pacific Journal of Clin Oncology 2009 Sep, 4(3):149-156
  22. Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med. 2009 Sep 3; 361(10):947-57
  23. Soo R, Mok T, Cho BC, Yang CH, Lim D, Goldstraw P. Anderson BO. First line systemic treatment of advanced stage non-small cell lung cancer: Consensus statement from Asian Oncology Summit 2009. Lancet Oncology 2009; 10: 1102–10
  24. Huang CL, Yang CH, Yeh KH, Hu FC, Chen KY, Shih JY, Lin ZZ, Yu CJ, Cheng AL, Yang PC. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer. 2009;64(3):346-51
  25. Lin CC and Yang CH* Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer. (Review) Target Oncol 2009;4(1):37-44 (*corresponding author)
  26. Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, Yu CJ, Yang CH, Lee YC, Yang PC, Shih JY. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 2009 20(4):696-702
  27. Lin MY, Chao PL, Fang SF, Chi CW, Yang CH Melatonin inhibits arsenite-induced peripheral neurotoxicity. J Pineal Res. 2009;46(1):64-70
  28. Yang CH*, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, Chen KY, Lin ZZ, Huang CJ, Shun CT, Huang CL, Bean J, Pao W and Yang PC. Specific EGFR mutations predict treatment outcome of stage III/IV chemonaive NSCLC patients receiving first-line gefitinib monotherapy. Journal of Clinical Oncology 2008;26:2745-2753 (*corresponding author)
  29. Yang CH*. EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer in East Asia: present and future (review) Lung Cancer 2008;60:S23-S30 supplement 2 (*corresponding author)
  30. Wu SG, Chang YL, Hsu YC, Wu JY, Yang CH, Yu CJ, Tsai MF, Shih JY, Yang PC. Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR) Mutations with the Classical Mutation Pattern. Oncologist. 2008;13(12):1276-84
  31. Wu JU, Yu CJ, Yang CH, Wu SG, Chiu YH, Gow CH, Chang YC, Hsu YC, Wei PF, Shih JY, Yang PC. First or second-line therapy with gefitinib produces equal survival in non small cell lung cancer. Am J Respir Crit Care Med. 2008 Oct 15;178(8):847-53.
  32. Wu SG, Gow CH, Yu CJ, Chang YL, Yang CH, Hsu YC, Shih JY, Lee YC, Yang PC. Frequent EGFR mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J. 2008 Oct;32(4):924-30
  33. Perng RP, Yang CH*, Chen YM, Chang GC, Lin gMC, Hsieh RK, Chu NM, Lai RS, Su WC, Tsa CJ, Hsia TC, Chen HC, Chen CH, Huang MS, Wang JL, Ho ML, Chung CY, Yu CJ, Chang WC, Kou HP, Yu CT, Lin ZZ Kao WY. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 2008 Oct;62(1):78-84 (co-corresponding author)
  34. Wu JY, WuSG, Yang CH, Gow CH, Chang YL, Yu CJ, Shih JY, Yang PC. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clinical Cancer Research 2008 Aug 1;14(15):4877-82.
  35. Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ, Lin CC, Huang TC, Yang PC, Yang CH*. Gemcitabine plus Conventional-dose Epirubicin versus Gemcitabine plus Cisplatin as First-line Chemotherapy for Stage IIIB/IV Non-Small Cell Lung Carcinoma-A randomized phase II trial Lung Cancer 2008;62,334-343 (*corresponding author)
  36. Lin CC, Pu YS, Hsu CH, Keng HY, Cheng AL and Yang CH*. Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 2008;26(6):659-61 (*corresponding author)
  37. Chou YH, Chao PL, Tsai MJ, Cheng HH, Chen KB, Yang DM, Yang CH* and Lin MY. Arsenite-induced cytotoxicity in dorsal root ganglion explants. Free Radical Biol. Med. 2008 April 15;44(8):1553-61. (*co-corresponding author)
  38. Chen JP, Lo Y, Yu CJ, Hsu C, Shih JY and Yang CH* Predictors of toxicity of weekly Docetaxel in chemotherapy-treated nonsmall cell lung cancers. Lung cancer 2008 Apr;60(1):92-7 (*corresponding author)
  39. Lin ZZ, Hsu C, Chang YC, Yu CJ, Hsu CH, Lin CC, Cheng AL, Yang PC and Yang CH* Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment. Lung Cancer 2008 May;60(2):215-21. (*corresponding author)
  40. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH and Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008 Jan;59(1):105-10.
  41. Gow CH, Chien CR, Chang YL, Chiu YH, Shih JY, Chang YC, Yu CJ, Yang CH and Yang PC. Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response Clinical Cancer Research 2008 Jan 1;14(1):162-8